Warren A James1, Elizabeth Ogunrinde2, Zhuang Wan2, Diane L Kamen3, Jim Oates3, Gary S Gilkeson4, Wei Jiang5. 1. W.A. James, MD, College of Medicine, Medical University of South Carolina. 2. E. Ogunrinde, PhD, Z. Wan, MS, Department of Microbiology and Immunology, Medical University of South Carolina. 3. D.L. Kamen, MD, J. Oates, Director and Endowed Chair, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, and Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina. 4. G.S. Gilkeson, MD, Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, and Staff Physician, Ralph H. Johnson VA Medical Center; gilkeson@musc.edu. 5. W. Jiang, MD, Department of Microbiology and Immunology, and Division of Infectious Diseases, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA. jianw@musc.edu.
Abstract
OBJECTIVE: Blood microbiome has been analyzed in cancer patients using machine learning. We aimed to study whether the plasma microbiome represents the microbial community in the gut among patients with systemic lupus erythematosus (SLE) and healthy controls (HCs). METHODS: Paired plasma and stool samples from female patients with SLE and female HCs were assessed for microbiome composition by microbial 16S ribosomal RNA sequencing. RESULTS: Decreased microbial alpha diversity in stool compared to plasma and distinct plasma and gut beta diversity were found in both HCs and patients with SLE. No difference in gut microbial diversity was found; however, plasma alpha diversity was decreased in patients with SLE compared to HCs. The predominant bacteria differed between plasma and stool in both groups. Although the predominant plasma and stool genus bacteria were similar in patients with SLE and HCs, some were clearly different. CONCLUSION: Compared to the gut, the plasma microbiome contained distinct community and greater heterogeneity, indicating that the predominant circulating microbiome may originate from sites (eg, oral or skin) other than the gastrointestinal tract. The decreased plasma but not gut alpha diversity in patients with SLE compared to HCs implies an altered plasma microbiome in SLE, which may be important for systemic immune perturbations and SLE disease pathogenesis.
OBJECTIVE: Blood microbiome has been analyzed in cancer patients using machine learning. We aimed to study whether the plasma microbiome represents the microbial community in the gut among patients with systemic lupus erythematosus (SLE) and healthy controls (HCs). METHODS: Paired plasma and stool samples from female patients with SLE and female HCs were assessed for microbiome composition by microbial 16S ribosomal RNA sequencing. RESULTS: Decreased microbial alpha diversity in stool compared to plasma and distinct plasma and gut beta diversity were found in both HCs and patients with SLE. No difference in gut microbial diversity was found; however, plasma alpha diversity was decreased in patients with SLE compared to HCs. The predominant bacteria differed between plasma and stool in both groups. Although the predominant plasma and stool genus bacteria were similar in patients with SLE and HCs, some were clearly different. CONCLUSION: Compared to the gut, the plasma microbiome contained distinct community and greater heterogeneity, indicating that the predominant circulating microbiome may originate from sites (eg, oral or skin) other than the gastrointestinal tract. The decreased plasma but not gut alpha diversity in patients with SLE compared to HCs implies an altered plasma microbiome in SLE, which may be important for systemic immune perturbations and SLE disease pathogenesis.
Authors: Puneet Puri; Suthat Liangpunsakul; Jeffrey E Christensen; Vijay H Shah; Patrick S Kamath; Gregory J Gores; Susan Walker; Megan Comerford; Barry Katz; Andrew Borst; Qigui Yu; Divya P Kumar; Faridoddin Mirshahi; Svetlana Radaeva; Naga P Chalasani; David W Crabb; Arun J Sanyal Journal: Hepatology Date: 2018-02-22 Impact factor: 17.425
Authors: Daniel F Zegarra-Ruiz; Asmaa El Beidaq; Alonso J Iñiguez; Martina Lubrano Di Ricco; Silvio Manfredo Vieira; William E Ruff; Derek Mubiru; Rebecca L Fine; John Sterpka; Teri M Greiling; Carina Dehner; Martin A Kriegel Journal: Cell Host Microbe Date: 2018-12-20 Impact factor: 21.023
Authors: S Manfredo Vieira; M Hiltensperger; V Kumar; D Zegarra-Ruiz; C Dehner; N Khan; F R C Costa; E Tiniakou; T Greiling; W Ruff; A Barbieri; C Kriegel; S S Mehta; J R Knight; D Jain; A L Goodman; M A Kriegel Journal: Science Date: 2018-03-09 Impact factor: 47.728
Authors: Taco A van der Meulen; Hermie J M Harmsen; Arnau Vich Vila; Alexander Kurilshikov; Silvia C Liefers; Alexandra Zhernakova; Jingyuan Fu; Cisca Wijmenga; Rinse K Weersma; Karina de Leeuw; Hendrika Bootsma; Fred K L Spijkervet; Arjan Vissink; Frans G M Kroese Journal: J Autoimmun Date: 2018-11-09 Impact factor: 7.094
Authors: Jason M Brenchley; David A Price; Timothy W Schacker; Tedi E Asher; Guido Silvestri; Srinivas Rao; Zachary Kazzaz; Ethan Bornstein; Olivier Lambotte; Daniel Altmann; Bruce R Blazar; Benigno Rodriguez; Leia Teixeira-Johnson; Alan Landay; Jeffrey N Martin; Frederick M Hecht; Louis J Picker; Michael M Lederman; Steven G Deeks; Daniel C Douek Journal: Nat Med Date: 2006-11-19 Impact factor: 53.440
Authors: Sanjay K Shukla; Dane Cook; Jacob Meyer; Suzanne D Vernon; Thao Le; Derek Clevidence; Charles E Robertson; Steven J Schrodi; Steven Yale; Daniel N Frank Journal: PLoS One Date: 2015-12-18 Impact factor: 3.240
Authors: Zhenwu Luo; Alexander V Alekseyenko; Elizabeth Ogunrinde; Min Li; Quan-Zhen Li; Lei Huang; Betty P Tsao; Diane L Kamen; Jim C Oates; Zihai Li; Gary S Gilkeson; Wei Jiang Journal: Front Microbiol Date: 2021-01-08 Impact factor: 5.640
Authors: Emma Whittle; Martin O Leonard; Rebecca Harrison; Timothy W Gant; Daniel Paul Tonge Journal: Front Microbiol Date: 2019-01-17 Impact factor: 5.640